DRMA Dermata Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1853816 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-7.4%
TTM EPS YoY-121.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-241.5%
ROA-162.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets41.1%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $2.93M | $8.20M |
| SG&A expense | $4.84M | $4.31M |
| Operating income | -$7.77M | -$12.51M |
| Income tax | — | $0 |
| Net income | -$7.56M | -$12.29M |
| EPS (basic) | -8.16 | -80.32 |
| EPS (diluted) | -8.16 | -80.32 |
| Weighted avg. shares (diluted) | 926,192 | 152,974 |
| Balance sheet | ||
| Cash & equivalents | $7.52M | $3.16M |
| Current assets | $7.86M | — |
| Total assets | $7.86M | $3.53M |
| Total liabilities | $1.64M | $1.97M |
| Shareholders' equity | $6.22M | $1.56M |
| Shares outstanding | 2.66M | 251,725 |
| Cash flow statement | ||
| Operating cash flow | -$7.76M | -$11.16M |
| Financing cash flow | $12.12M | $6.89M |
| Stock-based compensation | $143,732 | $657,649 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.